IKBKG (Ab-85) Antibody

Code CSB-PA177488
Size US$297
Image
  • Western blot analysis of extracts from HepG2 cells, treated with Anisomycin (0.5uM, 5hours), using IKK-γ (Ab-85) antibody.
  • Immunofluorescence analysis of HeLa cells, using IKK-γ (Ab-85) antibody.
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name
Rabbit anti-Homo sapiens (Human) IKBKG Polyclonal antibody
Uniprot No.
Target Names
IKBKG
Alternative Names
IkB kinase associated protein 1 antibody; IkB kinase subunit gamma antibody; Inhibitor of nuclear factor kappa B kinase subunit gamma antibody; AMCBX1 antibody; FIP 3 antibody; FIP-3 antibody; FIP3 antibody; Fip3p antibody; I kappa B kinase gamma antibody; I-kappa-B kinase subunit gamma antibody; IkB kinase gamma subunit antibody; IkB kinase subunit gamma antibody; IkB kinase-associated protein 1 antibody; Ikbkg antibody; IKK gamma antibody; IKK-gamma antibody; IKKAP1 antibody; IKKG antibody; IMD33 antibody; Incontinentia pigmenti antibody; Inhibitor of kappa light polypeptide gene enhancer in B cells, kinase gamma antibody; Inhibitor of kappa light polypeptide gene enhancer in B cells, kinase of, gamma antibody; Inhibitor of nuclear factor kappa-B kinase subunit gamma antibody; IP antibody; IP1 antibody; IP2 antibody; IPD2 antibody; NEMO antibody; NEMO_HUMAN antibody; NF kappa B essential modifier antibody; NF kappa B essential modulator antibody; NF-kappa-B essential modifier antibody; NF-kappa-B essential modulator antibody; ZC2HC9 antibody
Raised in
Rabbit
Species Reactivity
Human,Mouse
Immunogen
Synthesized non-phosphopeptide derived from Human IKK-γ around the phosphorylation site of serine 85 (Q-A-S(p)-Q-R).
Immunogen Species
Homo sapiens (Human)
Clonality
Polyclonal
Purification Method
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration
It differs from different batches. Please contact us to confirm it.
Form
Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Tested Applications
ELISA,WB,IF
Recommended Dilution
Application Recommended Dilution
WB 1:500-1:3000
IF 1:100-1:500
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Regulatory subunit of the IKK core complex which phosphorylates inhibitors of NF-kappa-B thus leading to the dissociation of the inhibitor/NF-kappa-B complex and ultimately the degradation of the inhibitor. Its binding to scaffolding polyubiquitin plays a key role in IKK activation by multiple signaling receptor pathways. Can recognize and bind both 'Lys-63'-linked and linear polyubiquitin upon cell stimulation, with a much higher affinity for linear polyubiquitin. Could be implicated in NF-kappa-B-mediated protection from cytokine toxicity. Essential for viral activation of IRF3. Involved in TLR3- and IFIH1-mediated antiviral innate response; this function requires 'Lys-27'-linked polyubiquitination.; (Microbial infection) Also considered to be a mediator for HTLV-1 Tax oncoprotein activation of NF-kappa-B.
Gene References into Functions
  1. Computational analysis identified two miR-107 binding sites in the 3'UTR of IKBKG suggesting that IKBKG expression is regulated by miR-107. PMID: 30396951
  2. Human IKKgamma does not interact with mammalian Atg8-family proteins. PMID: 29097655
  3. Data suggest the angiopoietin-like 8 (ANGPTL8)/p62-IKKgamma axis as a negative feedback loop that regulates NF-kappaB activation, and extends the role of selective autophagy in fine-tuned inflammatory responses. PMID: 29255244
  4. this study demonstrates immunodeficiency in two female patients with Incontinentia Pigmenti with heterozygous NEMO mutation diagnosed by lipopolysaccharide unresponsiveness PMID: 28702714
  5. GSK-3beta is critically important for ordered NF-kappaB signalling through modulation of NEMO phosphorylation. PMID: 27929056
  6. HOTAIR operates the action of IKKalpha, IKKbeta, IKKgamma in liver cancer stem cells PMID: 27367027
  7. the present study found that loss of the NEMO-SHARPIN interaction impaired recruitment of truncated NEMO forms into punctuate structures that are transiently formed on cell stimulation and thus led to a defect in linear ubiquitination PMID: 28249776
  8. NEMO was critically involved in the cGAS-STING pathway. PMID: 28939760
  9. Results show that NEMO's expression is regulated by ASAP3 which it interacts directly with it reducing its poly-ubiquitinylation. PMID: 28502111
  10. E+P treatment of breast cancer cells increased ER binding to the NEMO promoter, thereby increasing NEMO expression. PMID: 28515148
  11. Hematopoietic stem cell transplantation can cure most clinical features of patients with a variety of IKBKG mutations. PMID: 28679735
  12. Authors show that NEMO stabilizes HIFalpha via direct interaction and independently of NF-kappaB signaling in vitro. NEMO prolongs tumor cell survival via regulation of apoptosis and activation of epithelial-to-mesenchymal transition, facilitating tumor metastasis. PMID: 26500060
  13. The results demonstrate the the first example of father-to-daughter transmission of IP in which a pathogenic mutation in IKBKG has been demonstrated PMID: 27037530
  14. Molluscum contagiosum virus MC005 inhibited NF-kappaB proximal to the IkappaB kinase (IKK) complex, and unbiased affinity purification revealed that MC005 interacts with the IKK subunit NEMO (NF-kappaB essential modulator). PMID: 28490597
  15. These data suggest that molluscum contagiosum virus MC159 competitively binds to NEMO to prevent cIAP1-induced NEMO polyubiquitination. PMID: 28515292
  16. High IKBKG expression is associated with multiple myeloma. PMID: 27454822
  17. Our findings shed light on the nature of the interaction between NEMO and poly-ubiquitin, suggesting that NEMO is differentially regulated by poly-ubiquitin chain length and that this regulation occurs via a modulation of the available equilibrium of conformational states, rather than gross structural change PMID: 27028374
  18. FADD, as well as NEMO, is a substrate for LUBAC ubiquitin ligase (E3) complex, composed of the HOIP, HOIL-1L, and SHARPIN subunits. PMID: 28189684
  19. Consistent with experimental evidence, the zinc ion is essential for mechanical stabilization of the functional, folded conformation of NEMO. PMID: 28035815
  20. Herein, our simulations of the zinc finger NEMO (2JVX) using multiple simulations of length 15, 30, 1000, and 3000 ns are analyzed to provide clarity on this point. PMID: 25734227
  21. Deletion of exons 4 to 10 (NEMODelta4-10) accounts for about 80% of cases (familial and sporadic) of Incontinentia pigmenti. PMID: 26564087
  22. results further reveal that cFLIPLrequires the linear ubiquitin chain assembly complex and the kinase TAK1 for activation of the IKK kinase PMID: 26865630
  23. USP18 negatively regulates NF-kappaB signaling by targeting TAK1 and NEMO for deubiquitination through distinct mechanisms. PMID: 26240016
  24. A missense mutation in IKBKG causes a Nager syndrome or an atypical incontinentia pigmenti phenotype. IKBKG mutations are typically associated with preterm male death, but this variant is associated with survival for 8-15 days. PMID: 25441681
  25. Recruitment of A20 to the C-terminal domain of NEMO represents a novel mechanism limiting NF-kappaB activation by NEMO, and its absence results in autoinflammatory disease. PMID: 26802121
  26. Authors show that Rab11-GMPPNP-FIP3-Rabin8 is more stable than Rab11-GMPPNP-Rabin8, owing to direct interaction between Rabin8 and FIP3 within the dual effector-bound complex. PMID: 26258637
  27. Somatic mosaicism of a novel IKBKG nonsense mutation in a male patient with incontinentia pigmenti. PMID: 25944529
  28. COMMD7's binding to NEMO does not interfere with the binding to the IKKs, and that the disruption of the IKK complex through the use of the NBP competitor impairs the termination of NF-kappaB activity PMID: 26060140
  29. findings suggest that rare, functional variants in MYD88, IRAK4 or IKBKG do not significantly contribute to IPD susceptibility in adults at the population level PMID: 25886387
  30. the incontinentia pigmenti patients presented a common IKBKG exon 4-10 deletion PMID: 24073555
  31. A novel mutation, designated c.916G>A (p.D306N) is described. NEMO expression was unaffected, but ubiquitylation was decreased causing ectodermal dysplasia, immunodeficiency, incontinentia pigmenti, and immune thrombocytopenic purpura. PMID: 26117626
  32. IKKgamma is a parallel coiled-coil whose response to binding of vFLIP or IKKbeta is localized twisting. PMID: 25979343
  33. IPO3 binds NEMO, promotes its nuclear import, and is critical for DNA damage-dependent NF-kappaB activation. PMID: 26060253
  34. unanchored polyubiquitin has a role in regulation by inducing NEMO conformational change by an allosteric mechanism PMID: 25866210
  35. The stability of the NEMO coiled coil is maintained by strong interhelix interactions in the region centered on residue 54. PMID: 25400026
  36. Mass spectrometric analysis demonstrated that WA covalently modifies NEMO on a cysteine residue within the C-terminal zinc finger (ZF) domain. Point mutations to the ZF can reverse the WA-induced Lys-48-polyubiquitin binding phenotype PMID: 25296760
  37. NEMO patients without ectodermal dysplasia and anhidrosis have more robust immunologic responses. PMID: 24682681
  38. the rescuing of the binding affinity implies that a preordered IKK-binding region of NEMO is compatible with IKK binding, and the conformational heterogeneity observed in NEMO(44-111) may be an artifact of the truncation. PMID: 25286246
  39. IKBKG gene mutation was discovered as a cause for incontinentia pigmenti. (Meta-analysis) PMID: 23802866
  40. We report the results of genomic analysis for a girl with incontinentia pigmenti, but without NEMO mutation PMID: 24487970
  41. Data suggest the potential of targeting of Nemo-Like Kinase (NLK) to treat a range of tumourigenic conditions characterised by PTEN deficiency. PMID: 23144700
  42. 21 new point mutations have been reported, which further extend the spectrum of pathologic variants in Incontinentia pigmenti patients: premature stop codon, frameshift mutation, or a partial loss of NEMO/IKKgamma activity (splicing and missense). PMID: 24339369
  43. p62 interacts with NEMO, the regulatory subunit of the complex responsible for activation of NF-kappaB transcription factor. PMID: 24270048
  44. NEMO is essential for Kaposi's sarcoma-associated herpesvirus-encoded vFLIP K13-induced gene expression and protection against death receptor-induced cell death. PMID: 24672029
  45. Identified is a post-translational modification of NEMO - phosphorylation of residue 387. Phosphorylation of serine 387 is not an absolute requirement for NF-kappaB signalling. PMID: 24012789
  46. IKKgamma facilitates RhoA activation via a guanine nucletotide exchange factor, which in turn activates ROCK to phosphorylate IKKbeta, leading to NF-kappaB activation that induced the chemokine expression and cell migration upon TGF-beta1. PMID: 24240172
  47. Data suggest that all seven cysteines (4 in zinc finger domain) of NEMO (NF-kappaB essential modulator protein) can be simultaneously mutated to alanine without affecting binding affinity of NEMO for I-kappa B kinase beta catalytic subunit. PMID: 24266532
  48. USP10 inhibits genotoxic NF-kappaB activation by MCPIP1-facilitated deubiquitination of NEMO. PMID: 24270572
  49. Merkel cell polyomavirus small T antigen targets the NEMO adaptor protein to disrupt inflammatory signaling. PMID: 24109239
  50. NEMO ZF, like other NEMO related-ZFs, binds mono-Ub and di-Ub with distinct stoichiometries, indicating the presence of a new Ub site within the NEMO ZF. PMID: 24100029

Show More

Hide All

Involvement in disease
Ectodermal dysplasia, anhidrotic, with immunodeficiency X-linked (EDAID); Ectodermal dysplasia, anhidrotic, with immunodeficiency, osteopetrosis and lymphedema (OLEDAID); Immunodeficiency, NEMO-related, without anhidrotic ectodermal dysplasia (NEMOID); Immunodeficiency 33 (IMD33); Recurrent isolated invasive pneumococcal disease 2 (IPD2); Incontinentia pigmenti (IP)
Subcellular Location
Cytoplasm. Nucleus.
Tissue Specificity
Heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas.
Database Links

HGNC: 5961

OMIM: 300248

KEGG: hsa:8517

STRING: 9606.ENSP00000358622

UniGene: Hs.43505

Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
Address
7505 Fannin St., Ste 610, Room 322 (CUBIO Innovation Center), Houston, TX 77054, USA
Join Us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2023 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1